Guruprasad P. Aithal

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2K citations · Full text

Placebo-controlled Phase 2, Liraglutide Safety, Hepatology +5

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Thrombosis, Medicine, Genetic Epidemiology +12

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

EASL Clinical Practice Guidelines: Drug-induced liver injury

Raúl J. Andrade, Guruprasad P. Aithal, Einar S. Björnsson et al. · Journal of Hepatology · 2019 · 1.1K citations

Hepatology, Liver Physiology, Complications Of Cirrhosis +5

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 993 citations · Full text